Jan Pinkas
Direttore Tecnico/Scientifico/R&S presso PYXIS ONCOLOGY, INC.
Profilo
Jan Pinkas is currently the Chief Scientific Officer at Pyxis Oncology, Inc. He previously worked as the VP-Translational Research & Development at ImmunoGen, Inc. and as the Senior Vice President-Translation Services at Magenta Therapeutics, Inc. Dr. Pinkas received his undergraduate degree from The Johns Hopkins University and his doctorate degree from the University of Massachusetts.
Posizioni attive di Jan Pinkas
| Società | Posizione | Inizio |
|---|---|---|
| PYXIS ONCOLOGY, INC. | Direttore Tecnico/Scientifico/R&S | 12/04/2022 |
Precedenti posizioni note di Jan Pinkas
| Società | Posizione | Fine |
|---|---|---|
| IMMUNOGEN, INC. | Corporate Officer/Principal | - |
| MAGENTA THERAPEUTICS | Corporate Officer/Principal | - |
Formazione di Jan Pinkas
| University of Massachusetts | Doctorate Degree |
| The Johns Hopkins University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| PYXIS ONCOLOGY, INC. | Health Technology |
| IMMUNOGEN, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Magenta Therapeutics, Inc.
 Magenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Magenta Therapeutics, Inc. is a biotechnology company, which focuses on improving stem cell transplantation. Its platform includes MGTA-117, MGTA-145, and CD45-ADC. The company was founded by David T. Scadden, Derrick J. Rossi, Alan Tyndall, Luigi Naldini, Robert Negrin, John F. Dipersio, and Jason Gardner on June 17, 2015 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Jan Pinkas
